Summary
The ultimate goal of EHAB is to accelerate the delivery of innovative health techniques and products, in the area of advanced therapies/regenerative medicine and biomaterials to citizens and patients who need it. This innovative healthcare should be affordable for all and improve the quality of life of patients. With Advanced Therapies & Biomaterials it will be possible to have more effective and efficient healthcare for lots of common diseases, like orthopedics, cancer or cardiovascular. Currently it is very hard to bring these techniques to the market and companies face many barriers, from production challenges to regulation. Joint action at an EU level can make the difference. Ecosystems can work together to overcome the barriers of the companies to catalyze and speed up the process of bringing innovative AT&B products to the market. The first step in creating this value chain is to capitalize and connect the assets with EU innovation ecosystems and lay the foundation for an excellent partnership from different European regions.
EHAB’s Vision is thus to strengthen the European landscape in advanced therapies and biomaterials (AT&B) by building a European interconnected value chain and powerhouse to making cell and tissue related therapies available to all European citizens, seizing opportunities in key parts of the AT&B value chain, consolidating EU assets, notably SMEs and increasing its international competitiveness.
EHAB’s Mission is to identify regional strengths, weaknesses, gaps and needs in a joint transregional AT&B value chain and to elaborate an action plan to strengthen the performance and capacity of the innovation ecosystems, their efficient interconnection and their alignment towards EU-level priorities, jointly tackling challenges at EU, national and regional level together with the quadruple helix stakeholders from the deeptech SME community, funding agencies, investors, academia, service providers, notified bodies, policy makers, patients.
EHAB’s Vision is thus to strengthen the European landscape in advanced therapies and biomaterials (AT&B) by building a European interconnected value chain and powerhouse to making cell and tissue related therapies available to all European citizens, seizing opportunities in key parts of the AT&B value chain, consolidating EU assets, notably SMEs and increasing its international competitiveness.
EHAB’s Mission is to identify regional strengths, weaknesses, gaps and needs in a joint transregional AT&B value chain and to elaborate an action plan to strengthen the performance and capacity of the innovation ecosystems, their efficient interconnection and their alignment towards EU-level priorities, jointly tackling challenges at EU, national and regional level together with the quadruple helix stakeholders from the deeptech SME community, funding agencies, investors, academia, service providers, notified bodies, policy makers, patients.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/101134833 |
| Start date: | 01-12-2023 |
| End date: | 30-11-2024 |
| Total budget - Public funding: | - 499 210,00 Euro |
Cordis data
Original description
The ultimate goal of EHAB is to accelerate the delivery of innovative health techniques and products, in the area of advanced therapies/regenerative medicine and biomaterials to citizens and patients who need it. This innovative healthcare should be affordable for all and improve the quality of life of patients. With Advanced Therapies & Biomaterials it will be possible to have more effective and efficient healthcare for lots of common diseases, like orthopedics, cancer or cardiovascular. Currently it is very hard to bring these techniques to the market and companies face many barriers, from production challenges to regulation. Joint action at an EU level can make the difference. Ecosystems can work together to overcome the barriers of the companies to catalyze and speed up the process of bringing innovative AT&B products to the market. The first step in creating this value chain is to capitalize and connect the assets with EU innovation ecosystems and lay the foundation for an excellent partnership from different European regions.EHAB’s Vision is thus to strengthen the European landscape in advanced therapies and biomaterials (AT&B) by building a European interconnected value chain and powerhouse to making cell and tissue related therapies available to all European citizens, seizing opportunities in key parts of the AT&B value chain, consolidating EU assets, notably SMEs and increasing its international competitiveness.
EHAB’s Mission is to identify regional strengths, weaknesses, gaps and needs in a joint transregional AT&B value chain and to elaborate an action plan to strengthen the performance and capacity of the innovation ecosystems, their efficient interconnection and their alignment towards EU-level priorities, jointly tackling challenges at EU, national and regional level together with the quadruple helix stakeholders from the deeptech SME community, funding agencies, investors, academia, service providers, notified bodies, policy makers, patients.
Status
SIGNEDCall topic
HORIZON-EIE-2023-CONNECT-01-02Update Date
12-03-2024
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
Search
Organisations
-
| NV BRABANTSE ONTWIKKELINGS MAATSCHAPPIJ HOLDING BV (Coördinator)
-
| ASSOCIATION FOR THE ADVANCEMENT OF TISSUE ENGINEERING AND CELL BASED TECHNOLOGIES & THERAPIES
-
| BIOCAT LA FUNDACIO BIOREGIO DE CATALUNYA
-
| BIOREGIO STERN MANAGEMENT GMBH
-
| FLANDERSBIO
-
| GORNOSLASKI AKCELERATOR PRZEDSIEBIORCZOSCI RYNKOWEJ SP Z O.O.
-
| MAASTRICHT HEALTH CAMPUS BV
-
| SP SVERIGES TEKNISKA FORSKNINGSINSTITUT AB